ASO VISUAL ABSTRACT

ASO Visual Abstract: Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic

Austin D. Williams, MD, MSc¹, Cecilia Chang, MS², Elin R. Sigurdson, MD, PhD³, Chihsung Wang, PhD², Allison A. Aggon, DO³, Maureen V. Hill, MD³, Andrea Porpiglia, MD³, and Richard J. Bleicher, MD³

¹Department of Surgery, Lankenau Medical Center, Wynnewood, PA; ²Research Institute, NorthShore University HealthSystem, Evanston, IL; ³Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA

This analysis (<https://doi.org/10.1245/s10434-021-10883-5>) of a pre-pandemic cohort found that neoadjuvant endocrine therapy (NET) used as a bridge to surgery during

the SARS-CoV2 pandemic may offer protection from cancer invasion for patients with ductal carcinoma *in situ* (DCIS) who experience a delay in surgery.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.